Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE 1: CagriSema 2.4 mg/2.4 mg vs semaglutide vs cagrilintide vs placebo in overweight or obesity
jRCT2051220121Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial of CagriSema, semaglutide and cagrilintide in obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in body weight (%). Started Nov 2022; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051220121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220121.